Kamada Ltd.

Regulatory Filings • Jun 4, 2018

_________ false

����� ��"�	2 380
KAMADA LTD
Corporation no: 511524605	10991
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	04/06/2018
	www.isa.gov.il			www.tase.co.il				Reference:	2018-02-055072	Time of broadcast: 13:55 13:51:50

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	Delay the publication of a report	_________	_________

1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onResults of Kamada�s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be presented at the upcoming American Diabetes Association�s 78th Scientific Sessions

04062018_KAMADA_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: TASE	Date of revision of form structure: 01/05/2018
Address: Holtzman 2 4081 , Rehovot 7670402   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: liorf@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: Fhima Lior Position of Signatory in the reporting corporation: Director of Finance Name of Employer Company:
Address: Sapir 7 , Ness Ziona 7403630 Telephone: 08-9913168 Facsimile: 08-9912083 E-mail: liorf@kamada.com 2